Overview

The Study of Drug 601 in Patients With Diabetic Macular Edema (DME)

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Observe the safety and tolerability of the single and multiple doses of 601 in DME patients; study the pharmacokinetic characteristics of single and multiple doses of 601, Observe the Preliminary efficacy of 601 multiple injections with different doses in the treatment of patients with DME.
Phase:
Phase 1
Details
Lead Sponsor:
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Treatments:
Antibodies
Antibodies, Monoclonal
Bevacizumab
Immunoglobulins